Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 28 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque PsoriasisCompletedNCT03210961Phase 1Results posted
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03210714Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious UveitisTerminatedNCT03207815Phase 2Results posted
• Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)CompletedNCT03207555Phase 2Results posted
• Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT03206970Phase 2Results posted
• Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03206918Phase 2Results posted
• Nilotinib in Parkinson's DiseaseCompletedNCT03205488Phase 2Results posted
• A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell MalignanciesTerminatedNCT03205046Phase 1/2Results posted
• Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03204188Phase 2Results posted
• Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKDCompletedNCT03203642Phase 2Results posted
• Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel DiseaseTerminatedNCT03201445Phase 2Results posted
• Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaTerminatedNCT03201250Phase 1/2Results posted
• Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor TreatmentCompletedNCT03200717Phase 2Results posted
• Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's LymphomasActive, not recruitingNCT03198026Phase 2Results posted
• A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerCompletedNCT03194893Phase 3Results posted
• A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p DeletionCompletedNCT03190330Phase 4Results posted
• A Study to Investigate Zanubrutinib in Chinese Participants With B-cell LymphomaCompletedNCT03189524Phase 1Results posted
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT03184571Phase 2Results posted
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBCTerminatedNCT03184558Phase 2Results posted
• A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) MutationCompletedNCT03182244Phase 3Results posted
• A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing SpondylitisCompletedNCT03178487Phase 2Results posted
• A Study of ONO-7475 in Patients With Acute LeukemiasTerminatedNCT03176277Phase 1/2Results posted
• Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell CarcinomaCompletedNCT03173560Phase 2Results posted
• A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/2Results posted
• Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the LungCompletedNCT03157089Phase 2Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• Ruxolitinib in Operable Head and Neck CancerTerminatedNCT03153982Phase 2Results posted
• Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03149822Phase 1/2Results posted
• Inhibition of Anaphylaxis by IbrutinibCompletedNCT03149315Phase 2Results posted
• Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome PatientsTerminatedNCT03145480Phase 2Results posted
• Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell LymphomaCompletedNCT03145064Phase 2Results posted
• A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With MyelofibrosisCompletedNCT03144687Phase 2Results posted
• A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedNCT03141177Phase 3Results posted
• GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host DiseaseCompletedNCT03139604Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia AreataCompletedNCT03137381Phase 2Results posted
• A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).CompletedNCT03137069Phase 2Results posted
• Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese AdultsTerminatedNCT03135028Phase 1Results posted
• Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)CompletedNCT03134222Phase 2Results posted
• QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell SarcomaTerminatedNCT03132155Phase 2Results posted
• LAM Pilot Study With Imatinib MesylateCompletedNCT03131999Phase 1/2Results posted
• A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid CancerTerminatedNCT03131206Phase 1/2Results posted
• Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT03128411Phase 2Results posted
• Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)TerminatedNCT03123588Phase 2Results posted
• TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT03123393Phase 2Results posted
• Ibrutinib, Nivolumab and Blinatumomab in Richter TransformationTerminatedNCT03121534Phase 2Results posted
• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)CompletedNCT03112603Phase 3Results posted
• Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise TestingCompletedNCT03109015Phase 2Results posted
• NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)CompletedNCT03107988Phase 1Results posted
• Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsCompletedNCT03106779Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)CompletedNCT03104400Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic DrugCompletedNCT03104374Phase 3Results posted
• Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's SyndromeCompletedNCT03100942Phase 2Results posted
• Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRCTerminatedNCT03099486Phase 2Results posted
• A Study of INCB018424 Phosphate Cream in Subjects With VitiligoCompletedNCT03099304Phase 2Results posted
• A Study of LY3337641 in Healthy ParticipantsCompletedNCT03099148Phase 1Results posted
• Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and NeratinibCompletedNCT03094052Phase 2Results posted
• Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract CancerCompletedNCT03093870Phase 2/3Results posted
• Savolitinib vs. Sunitinib in MET-driven PRCC.Active, not recruitingNCT03091192Phase 3Results posted
• Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung CancerCompletedNCT03088930Phase 2Results posted
• A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid MalignanciesCompletedNCT03088878Phase 1/2Results posted
• A Study of LY3337641 in Japanese and Caucasian Healthy ParticipantsCompletedNCT03083561Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's DiseaseCompletedNCT03077412Phase 2Results posted
• A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to ErlotinibCompletedNCT03076164Phase 1/2Results posted
• Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast CancerCompletedNCT03054363Phase 1/2Results posted
• A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)CompletedNCT03053440Phase 3Results posted
• A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCActive, not recruitingNCT03052608Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)CompletedNCT03046056Phase 2Results posted
• Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLLCompletedNCT03045328Phase 2Results posted
• Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerCompletedNCT03043313Phase 2Results posted
• A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric CancerCompletedNCT03042611Phase 3Results posted
• Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar RhabdomyosarcomaTerminatedNCT03041701Phase 1/2Results posted
• Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03041636Phase 2Results posted
• Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular CancerCompletedNCT03037437Phase 2Results posted
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedNCT03037385Phase 1/2Results posted
• Baricitinib in Relapsing Giant Cell ArteritisCompletedNCT03026504Phase 2Results posted
• Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid ArthritisCompletedNCT03025308Phase 3Results posted
• Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney CancerCompletedNCT03015740Phase 1/2Results posted
• CISPLATIN + AZD-1775 In Breast CancerCompletedNCT03012477Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic DermatitisCompletedNCT03011892Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)CompletedNCT03011372Phase 2Results posted
• Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaCompletedNCT03010358Phase 1/2Results posted
• Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by SurgeryCompletedNCT03008369Phase 2Results posted
• A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaCompletedNCT03006926Phase 1Results posted
• Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT03006887Phase 1Results posted
• A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIACompletedNCT03000439Phase 3Results posted
• Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)CompletedNCT02999178Phase 3Results posted
• Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic LeukemiaCompletedNCT02997761Phase 2Results posted
• T790M Plasma Testing Methodology Comparison and Clinical ValidationCompletedNCT02997501Phase 3Results posted
• A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)CompletedNCT02997202Phase 3Results posted
• Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) MutationCompletedNCT02984995Phase 2Results posted
• Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02983617Phase 2Results posted
• A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350CompletedNCT02983227Phase 2Results posted
• A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLCStatus unknownNCT02981108Phase 1/2Results posted
• Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and NeckCompletedNCT02979977Phase 2Results posted
• Sitravatinib in Advanced Liposarcoma and Other Soft Tissue SarcomasCompletedNCT02978859Phase 2Results posted
• A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated MelanomaCompletedNCT02975700Not applicableResults posted
• A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple SclerosisTerminatedNCT02975349Phase 2Results posted
• A Phase II Study of M2951 in SLETerminatedNCT02975336Phase 2Results posted
• Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia AreataCompletedNCT02974868Phase 2Results posted
• Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02974621Phase 2Results posted

← Tyrosine Kinase Inhibitors overview